XBiotech Inc. filings document governance, executive-compensation, shareholder-vote, and material-agreement disclosures for a British Columbia biopharmaceutical issuer. Recent Form 8-K reports cover board appointments, committee assignments, amendments to director information, executive employment arrangements, and annual meeting voting results.
The company’s proxy materials describe director elections, auditor ratification, advisory compensation votes, and equity incentive plan matters. These filings provide the formal record for XBiotech’s board structure, compensation oversight, shareholder voting mechanics, and related public-company governance actions.
XBiotech Inc. granted Co-Chief Executive Officer Jan-Paul Simard 2,000,000 stock options to purchase common stock on October 26, 2026, under the 2025 Equity Incentive Plan; following the grant, he directly held 2,000,000 options. The options carry a $1.85-per-share exercise price and expire October 26, 2036. One-sixth vest on the 180th day after the grant, with an additional one-sixth vesting every six months thereafter, subject to the Executive Employment Agreement.
XBiotech Inc. reports that Co-Chief Executive Officer Jan-Paul Simard beneficially owned no securities or derivative securities before the option grant described in a Form 4 filed contemporaneously.
XBiotech Inc. director and ten percent owner John Simard purchased 368,524 shares of Common Stock from Thorpe McKenzie on October 26, 2026, at $1.93 per share. His direct holdings following the purchase were 4,191,690 shares. No Rule 10b5-1 plan is reported for the purchase.
XBiotech Inc. (XBIT) appointed Dr. Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers effective October 23, 2026. Dr. Shivaswamy will continue as chief scientific officer and receive an annual salary of $750,000. Jan-Paul Simard is the son of John Simard, the company's founder, chairman and former president and chief executive officer.
Jan-Paul Simard’s employment agreement, dated October 26, 2026, provides an annual base salary of $150,000, prorated through the end of 2026 and continuing through 2027, and a one-time grant of 2,000,000 stock options exercisable over ten years. One-sixth of the options vest on the 180th date after the agreement’s Effective Date, with another one-sixth vesting every six months until all are scheduled to vest within three years. If employment ends before full vesting, he may retain options in proportion to the portion of the three-year period he was employed; other options are forfeited.
XBiotech Inc. asked shareholders to vote at its November 24, 2026 virtual annual meeting on five director nominees, ratification of Whitley Penn LLP as auditor for the fiscal year ending December 31, 2026, and advisory approval of named executive compensation. The Board recommends voting for all three proposals. Shareholders of record on September 25, 2026 were eligible to vote; 30,487,731 common shares were outstanding on that date.
The 2025 compensation table reports $30,134,204 in total compensation for John Simard, former President and CEO, including $17,341,326 in severance, $8,530,442 in bonuses and $3,000,000 in option awards. Dr. Sushma Shivaswamy, interim CEO and Chief Scientific Officer, had total compensation of $570,992, and Director of Finance Angela Hu had total compensation of $245,419. Shivaswamy’s annual salary increased from $450,000 to $750,000 while she served in those roles.
XBiotech Inc. reported a net loss of $6.7 million for the quarter and $12.2 million for the six months ended June 30, 2026, similar to the $12.6 million loss in the prior-year period. There was no revenue, and the company does not expect to generate revenue in 2026 as it remains a clinical-stage biopharmaceutical developer.
Operating expenses declined materially: six‑month research and development costs fell to $10.5 million from $17.0 million, and general and administrative expenses decreased to $1.9 million from $2.9 million, partly reflecting the absence of a large 2025 bonus and option grant to the former CEO. Foreign exchange swung to a $2.5 million loss from a $3.4 million gain, limiting improvement in bottom-line results.
XBiotech ended the quarter with $109.5 million in cash and cash equivalents and $128.5 million of shareholders’ equity, with minimal liabilities and no outstanding debt. Management states this cash is expected to fund operations for at least 12 months and to complete key clinical inflection points, including Phase II trials for IL‑1a‑targeting antibodies in oncology and axial spondyloarthritis. A workforce reduction was implemented after quarter-end, with related costs not expected to be material. Disclosure controls and internal control over financial reporting were assessed as effective.
XBiotech Inc. reported a net loss of $5.5 million for the three months ended March 31, 2026, an improvement from a $10.9 million loss a year earlier. Loss per share narrowed to $0.18 from $0.36 on a stable share count of 30,487,731.
Total operating expenses fell sharply as research and development dropped to $5.2 million from $11.6 million and general and administrative costs declined to $1.1 million from $1.9 million, largely reflecting lower bonuses and stock-based compensation linked to the former CEO.
The company ended the quarter with cash and cash equivalents of $115.5 million and total assets of $139.8 million, against shareholders’ equity of $135.0 million. Management states this cash should fund operations for at least 12 months, but it does not expect any revenue in 2026 and anticipates continued operating losses as it advances its True Human™ antibody pipeline.
XBiotech Inc. filed an amended annual report to add detailed Part III disclosures on directors, executive compensation, ownership and equity plans for the year ended December 31, 2025. As of March 13, 2026, 30,487,731 common shares were outstanding and non‑affiliate equity had a market value of about $77.1 million as of June 30, 2025.
Former CEO John Simard received 2025 total compensation of about $30.1 million, including salary, bonuses, option awards and severance, while the median employee earned $87,096, resulting in a CEO pay ratio of roughly 345:1. The filing also describes board committee structures, director pay, and the transition from the expired 2015 equity plan to a new 2025 plan covering up to 8.38 million shares.
XBiotech Inc. filed its annual report describing a pre-market biopharmaceutical business focused on True Human monoclonal antibodies, particularly IL‑1α therapies for cancer, arthritis and stroke, plus an infectious disease pipeline. The company previously received $750 million from selling Bermekimab and has returned $495 million to shareholders via buybacks and dividends.
XBiotech recorded a net loss for 2025 and spent about $47.4 million on research and development, reflecting ongoing heavy investment without product revenue. As of March 13, 2026, 30,487,731 common shares were outstanding and the company employed 85 full‑time staff while emphasizing extensive clinical, regulatory, financing and commercialization risks.